October 1991
Volume 32, Issue 11
Free
Articles  |   October 1991
Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes.
Author Affiliations
  • K K Assil
    Bethesda Eye Institute, St. Louis University, Missouri 63110.
  • M Hartzer
    Bethesda Eye Institute, St. Louis University, Missouri 63110.
  • R N Weinreb
    Bethesda Eye Institute, St. Louis University, Missouri 63110.
  • M Nehorayan
    Bethesda Eye Institute, St. Louis University, Missouri 63110.
  • T Ward
    Bethesda Eye Institute, St. Louis University, Missouri 63110.
  • M Blumenkranz
    Bethesda Eye Institute, St. Louis University, Missouri 63110.
Investigative Ophthalmology & Visual Science October 1991, Vol.32, 2891-2897. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K K Assil, M Hartzer, R N Weinreb, M Nehorayan, T Ward, M Blumenkranz; Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes.. Invest. Ophthalmol. Vis. Sci. 1991;32(11):2891-2897.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

The effects of the antimetabolites, cytarabine (Ara-C) and 5-fluorouridine 5'-monophosphate (FUMP), encapsulated in multivesicular liposomes on formation of vitreous fibroproliferative membranes in New Zealand white (NZW) rabbits were studied. In pharmacokinetic studies, the drug half-life in the vitreous cavity was 124 hr after intravitreal administration of 1.0 mg of FUMP in liposomes. By contrast, the drug half-life after a single injection in nonliposome-treated controls was only 4.5 hr. In a heterologous dermal fibroblast model of proliferative vitreoretinopathy (PVR), there was a 92% decrease in frequency of tractional retinal detachments in rabbits receiving a single intravitreal injection of liposome-encapsulated 0.1 mg of FUMP compared with controls receiving liposomes without drug. A dose of 1 mg of Ara-C in liposome-treated rabbits was associated with only a 46% reduction in tractional detachment compared with controls. Multivesicular liposome-encapsulated FUMP may be useful for inhibiting formation of fibroproliferative membranes in the vitreous after vitreoretinal surgery.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×